Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Guggenheim

Research analysts at Guggenheim started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report released on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 310.96% from the company’s current price.

Other research analysts have also issued research reports about the stock. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Jefferies Financial Group raised their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Piper Sandler assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target on the stock. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.38.

Compass Therapeutics Price Performance

Shares of CMPX opened at $2.92 on Monday. The business’s 50-day moving average is $2.43 and its 200-day moving average is $1.89. Compass Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $4.08. The company has a market capitalization of $401.76 million, a price-to-earnings ratio of -7.89 and a beta of 1.17.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently bought and sold shares of the stock. MPM Bioimpact LLC boosted its holdings in Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after acquiring an additional 2,926,002 shares during the last quarter. Enavate Sciences GP LLC purchased a new position in Compass Therapeutics during the fourth quarter worth about $11,293,000. Tang Capital Management LLC grew its position in Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. Rock Springs Capital Management LP increased its stake in Compass Therapeutics by 2.7% in the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock valued at $8,380,000 after buying an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP lifted its position in shares of Compass Therapeutics by 2.6% during the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock worth $4,284,000 after buying an additional 75,000 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.